Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Impact of Atopic Dermatitis Lesion Location on Quality of Life in Adult Patients in a Real-world Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Clinical Relevance of Skin Pain in Atopic Dermatitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Persistence and Failure Rates of Monotherapy Etanercept in Biologic-Naïve Psoriasis Patients: A Retrospective Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Clinical Relevance of Skin Pain in Atopic Dermatitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Management of Ocular Manifestations of Atopic Dermatitis: A Consensus Meeting Using a Modified Delphi Process

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cost of Treating Skin Problems in Patients with Diabetes who Use Insulin Pumps and/or Glucose Sensors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Peter A Lio
  • Andreas Wollenberg
  • Jacob P Thyssen
  • Evangeline J Pierce
  • Maria Jose Rueda
  • Amy M DeLozier
  • Jorge Alfonso Ross Terres
  • Peter Anderson
  • Gary Milligan
  • James Piercy
  • Jonathan I Silverberg
  • Carle Paul
Vis graf over relationer

BACKGROUND: Atopic dermatitis (AD) has a negative impact on patients’ quality of life (QoL).

OBJECTIVE: To report the impact of specific AD lesion locations on QoL in adult patients with AD using real-world data.

METHODS: The Adelphi US Disease Specific Programme was conducted between January–April 2018. Physicians documented patient demographics/characteristics, AD lesion locations, and body surface area; patients completed questionnaires reporting the impact of lesion locations on QoL.

RESULTS: AD severity was moderate in 51.6% of patients and severe in 6.0%. Lesions were commonly identified in more than one location. All AD lesion locations impacted QoL. Visible areas were most bothersome, including head/neck (68%), hands/fingers (58%), front (30%), upper extremities (22%), and lower extremities (16%), with statistically significant associations for a number of Dermatology Life Quality Index (DLQI) items. Itch, soreness, pain, and stinging are also associated with a number of body areas but in particular with those that are most visible/accessible. Lesions on the head/neck and hands/fingers (58%) demonstrated an increased impact on the anxiety and depression dimension of the EuroQol 5-Dimension tool.

CONCLUSIONS: In patients with AD, quality of life was most affected in patients with lesions in visible areas, including head/neck, hands/fingers, and upper extremities, with statistically significant associations for a number of DLQI domains. Physicians should be aware of the burden of AD lesions on QoL and consider having conversations with patients to better understand the impact of these lesions. Prior presentation: 28th Annual European Academy of Dermatology and Venereology Congress; 9–13 October 2019, Madrid, Spain. Poster number P0233.J Drugs Dermatol. 2020;19(10): 943-948. doi:10.36849/JDD.2020.5422.

OriginalsprogEngelsk
TidsskriftJournal of drugs in dermatology : JDD
Vol/bind19
Udgave nummer10
Sider (fra-til)943-948
Antal sider6
ISSN1545-9616
DOI
StatusUdgivet - 1 okt. 2020

ID: 60994639